AtriCure (ATRC) Stock Price, News & Analysis

Company Overview

AtriCure, Inc. is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques. In addition, AtriCure markets the LARIAT Suture Delivery Device for left atrial appendage closure to help reduce stroke risk in AF patients who are unable to tolerate long-term anticoagulation therapy. AtriCure continues to invest in R&D initiatives aimed at expanding its surgical and hybrid EP solutions, as well as digital platforms for intraoperative mapping and post-procedural monitoring.

AtriCure operates internationally with sales and distribution channels across North America, Europe, Asia and select emerging markets. The company collaborates with leading cardiac centers, physician innovators and academic institutions to conduct clinical studies and training programs that support adoption of its technologies. Under the leadership of President and Chief Executive Officer Jonathan M. Cathcart, AtriCure has pursued strategic partnerships and targeted acquisitions to enhance its electrophysiology portfolio and drive long-term growth. The company remains committed to expanding access to safe, effective AF treatments and advancing the standard of care in cardiac surgery and electrophysiology.

Key Stats

• Today's Range: $27.14 to $29.19
• 50-Day Range: $27.34 to $31.64
• 52-Week Range: $26.62 to $43.18
• Volume: 1.01 million shs
• Average Volume: 712,620 shs
• Market Capitalization: $1.41 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $48.71
• Consensus Rating: Moderate Buy

AtriCure Stock Analysis - MarketRank™

AtriCure scored higher than 78% of companies evaluated by MarketBeat, and ranked 165th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AtriCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 1 strong buy rating, 6 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

AtriCure has a consensus price target of $48.71, representing about 75.2% upside from its current price of $27.80.

Amount of Analyst Coverage

AtriCure has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 250.00%

Earnings Growth

Earnings for AtriCure are expected to grow by 250.00% in the coming year, from $0.10 to $0.35 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AtriCure is -278.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AtriCure is -278.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AtriCure has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.40% of the float of AtriCure has been sold short.

Short Interest Ratio / Days to Cover

AtriCure has a short interest ratio ("days to cover") of 5.65.

Change versus previous month

Short interest in AtriCure has recently increased by 2.07%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AtriCure does not currently pay a dividend.

Dividend Growth

AtriCure does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.75

News Sentiment

AtriCure has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for AtriCure this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for ATRC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $149,150.00 in company stock.

Percentage Held by Insiders

4.00% of the stock of AtriCure is held by insiders.

Percentage Held by Institutions

99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATRC Stock Analysis - Frequently Asked Questions

How have ATRC shares performed this year?

AtriCure's stock was trading at $39.56 at the start of the year. Since then, ATRC shares have decreased by 29.7% and is now trading at $27.80.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings data on Tuesday, May, 5th. The medical device company reported $0.00 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.07. The firm's revenue was up 14.3% on a year-over-year basis.
Read the conference call transcript.

Does AtriCure have any subsidiaries?

The following companies are subsidiaries of AtriCure: SentreHEART.

Who are AtriCure's major shareholders?

AtriCure's top institutional shareholders include Dimensional Fund Advisors LP (1.97%), WCM Investment Management LLC (0.71%), Wasatch Advisors LP (0.50%) and Bank of New York Mellon Corp (0.26%). Insiders that own company stock include Salvatore Privitera, Vinayak Doraiswamy, Justin J Noznesky, Karl S Dahlquist, Sven Wehrwein, Regina E Groves, Karen Prange and Maggie Yuen.
View institutional ownership trends.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/07/2026
• Bank of America Global Healthcare Conference 2026: 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:ATRC
• CIK: 1323885
• Web: www.atricure.com
• Phone: (513) 755-4100
• Fax: 513-755-4567
• Employees: 1,300
• Year Founded: 2000

Price Target and Rating

• Average Price Target for AtriCure: $48.71
• High Price Target: $55.00
• Low Price Target: $36.00
• Potential Upside/Downside: +75.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 278.00
• P/E Growth: N/A
• Net Income: -$11.45 million
• Net Margins: -0.83%
• Pretax Margin: -1.90%
• Return on Equity: 0.29%
• Return on Assets: 0.22%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 3.96
• Quick Ratio: 2.99

Sales & Book Value

• Annual Sales: $534.53 million
• Price / Sales: 2.63
• Cash Flow: $0.30 per share
• Price / Cash Flow: 93.90
• Book Value: $9.89 per share
• Price / Book: 2.81

Miscellaneous

• Outstanding Shares: 50,635,000
• Free Float: 48,610,000
• Market Cap: $1.41 billion
• Optionable: Optionable
• Beta: 1.28